Current Trials

locally advanced or metastatic non-small cell lung cancer previously treated with systemic cytotoxic therapy (or ineligible), and an immune checkpoint inhibitor (as monotherapy or in combination with systemic cytotoxic chemotherapy, or ineligible)

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).

This clinical trial is recruiting people with non-small cell lung cancer (NSCLC) that cannot be removed through surgery or that has spread to other parts of the body.

AcceleRET-Lung: A clinical trial to compare a medicine called pralsetinib with standard-of-care chemotherapy treatments in people with non-small cell lung cancer (NSCLC).

The target population for this study are Mayo Stage IV AL amyloid patients

This study is a Phase III, global, randomised double-blind trial of birtamimab plus standard of care vs placebo plus standard of care in Mayo Stage IV AL amyloid patients

Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment.

This study will also evaluate tumor markers and pharmacokinetics (PK) of zolbetuximab, Nab-P and GEM, and health-related quality of life (HRQoL).

Relapsed/Refractory Acute Myeloid Leukemia (AML)

This Study is to Determine the Effficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukaemia

Melanoma.

This study will evaluate the efficacy of NKTR-214 Combined with Nivolumab Versus Nivolumab

Melanoma.

The study will compare the pharmacokinetics of BMSCHO1-Nivolumab Process D to Nivolumab Process C

Previously untreated or unresectable or Metastatic Melanoma

The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread.

Participants with previously untreated Stage IV Non-Small Cell Lung Cancer.

The objective of the trial is to confirm the dose safety of combination relatlimab and nivolumab plus chemo and to compare the progression free survival for patients with untreated stage IV Non-Small Cell Lung Cancer or Recurrent Non-small Cell Lung Cancer.

Previously untreated Chronic Lymphocytic Leukaemia (CLL)

This trial will compare the efficacy of continuous ibrutinib monotherapy with fixed-duration venetoclax plus obinutuzumab and fixed-duration ibrutinib plus venetoclax in patients with previously untreated CLL

intermediate and high-risk oropharyngeal
cancer

To examine the outcomes of alternative treatments aiming to improve overall survival time in intermediate and high-risk oropharyngeal cancer and to compare Quality of Life (QoL), toxicity outcomes and swallowing function of these alternative treatments

The target population for this study are patients with relapsed/refractory multiple myeloma (MM). Patients will have a confirmed diagnosis of MM, with measurable disease as per IMWG criteria, in the second relapse and beyond (third line of therapy and beyond)

This study is a Phase Ib, open label, single arm, adaptive multi-centre clinical study of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in patients with relapsed/refractory multiple myeloma

Multiple types of cancer.

This study will evaluate the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy

People aged 18 years or older with either very high-risk localised prostate cancer, or very high risk features with PSA persistence or rise within one year following radical prostatectomy, suitable for Radiotherapy.

Determine the effectiveness of adding Darolutamide to androgen deprivation therapy (ADT) and radiation therapy in either the primary definitive setting or very high risk postoperative setting.

HER-2 positive metastatic and/or unresectable gastric or gasto-esophageal junction (GEJ) cancer

This study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd), a HER-2 targeting antinbody drug, compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) cancer who have progressed on or after a trastuzumab-containing regimen and have not received any additional systemic therapy.